296 related articles for article (PubMed ID: 21880986)
1. CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.
Qui HZ; Hagymasi AT; Bandyopadhyay S; St Rose MC; Ramanarasimhaiah R; Ménoret A; Mittler RS; Gordon SM; Reiner SL; Vella AT; Adler AJ
J Immunol; 2011 Oct; 187(7):3555-64. PubMed ID: 21880986
[TBL] [Abstract][Full Text] [Related]
2. An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.
Mittal P; Abblett R; Ryan JM; Hagymasi AT; Agyekum-Yamoah A; Svedova J; Reiner SL; St Rose MC; Hanley MP; Vella AT; Adler AJ
J Immunol; 2018 Feb; 200(4):1513-1526. PubMed ID: 29305435
[TBL] [Abstract][Full Text] [Related]
3. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent.
Lee SJ; Rossi RJ; Lee SK; Croft M; Kwon BS; Mittler RS; Vella AT
J Immunol; 2007 Aug; 179(4):2203-14. PubMed ID: 17675480
[TBL] [Abstract][Full Text] [Related]
4. CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion.
St Rose MC; Taylor RA; Bandyopadhyay S; Qui HZ; Hagymasi AT; Vella AT; Adler AJ
Immunol Cell Biol; 2013 Feb; 91(2):173-83. PubMed ID: 23295363
[TBL] [Abstract][Full Text] [Related]
5. Self-antigen prevents CD8 T cell effector differentiation by CD134 and CD137 dual costimulation.
Bandyopadhyay S; Long M; Qui HZ; Hagymasi AT; Slaiby AM; Mihalyo MA; Aguila HL; Mittler RS; Vella AT; Adler AJ
J Immunol; 2008 Dec; 181(11):7728-37. PubMed ID: 19017962
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy.
Mittal P; St Rose MC; Wang X; Ryan JM; Wasser JS; Vella AT; Adler AJ
J Immunol; 2015 Dec; 195(12):5816-26. PubMed ID: 26561553
[TBL] [Abstract][Full Text] [Related]
7. Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype.
Hirschhorn-Cymerman D; Budhu S; Kitano S; Liu C; Zhao F; Zhong H; Lesokhin AM; Avogadri-Connors F; Yuan J; Li Y; Houghton AN; Merghoub T; Wolchok JD
J Exp Med; 2012 Oct; 209(11):2113-26. PubMed ID: 23008334
[TBL] [Abstract][Full Text] [Related]
8. A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptors.
Konstorum A; Vella AT; Adler AJ; Laubenbacher RC
Sci Rep; 2019 Jul; 9(1):10862. PubMed ID: 31350431
[TBL] [Abstract][Full Text] [Related]
9. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
10. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
[TBL] [Abstract][Full Text] [Related]
11. High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome.
Dumitriu IE; Baruah P; Finlayson CJ; Loftus IM; Antunes RF; Lim P; Bunce N; Kaski JC
Circ Res; 2012 Mar; 110(6):857-69. PubMed ID: 22282196
[TBL] [Abstract][Full Text] [Related]
12. A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice.
Ryan JM; Mittal P; Menoret A; Svedova J; Wasser JS; Adler AJ; Vella AT
Cancer Immunol Immunother; 2018 Apr; 67(4):605-613. PubMed ID: 29327109
[TBL] [Abstract][Full Text] [Related]
13. Costimulation Endows Immunotherapeutic CD8 T Cells with IL-36 Responsiveness during Aerobic Glycolysis.
Tsurutani N; Mittal P; St Rose MC; Ngoi SM; Svedova J; Menoret A; Treadway FB; Laubenbacher R; Suárez-Ramírez JE; Cauley LS; Adler AJ; Vella AT
J Immunol; 2016 Jan; 196(1):124-34. PubMed ID: 26573834
[TBL] [Abstract][Full Text] [Related]
14. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo.
De Smedt T; Smith J; Baum P; Fanslow W; Butz E; Maliszewski C
J Immunol; 2002 Jan; 168(2):661-70. PubMed ID: 11777959
[TBL] [Abstract][Full Text] [Related]
15. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin.
Curran MA; Geiger TL; Montalvo W; Kim M; Reiner SL; Al-Shamkhani A; Sun JC; Allison JP
J Exp Med; 2013 Apr; 210(4):743-55. PubMed ID: 23547098
[TBL] [Abstract][Full Text] [Related]
16. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function.
Lee SJ; Myers L; Muralimohan G; Dai J; Qiao Y; Li Z; Mittler RS; Vella AT
J Immunol; 2004 Sep; 173(5):3002-12. PubMed ID: 15322159
[TBL] [Abstract][Full Text] [Related]
17. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
Redmond WL; Triplett T; Floyd K; Weinberg AD
PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
[TBL] [Abstract][Full Text] [Related]
18. Growth and differentiation advantages of CD4+ OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients.
Shindo T; Ishikawa T; Fukunaga A; Hori T; Uchiyama T
Biol Blood Marrow Transplant; 2008 Mar; 14(3):268-81. PubMed ID: 18275893
[TBL] [Abstract][Full Text] [Related]
19. OX40 signals during priming on dendritic cells inhibit CD4 T cell proliferation: IL-4 switches off OX40 signals enabling rapid proliferation of Th2 effectors.
Kim MY; Bekiaris V; McConnell FM; Gaspal FM; Raykundalia C; Lane PJ
J Immunol; 2005 Feb; 174(3):1433-7. PubMed ID: 15661901
[TBL] [Abstract][Full Text] [Related]
20. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I
Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
